Phase 3 Clinical Trial Initiated for Cystic Fibrosis Patients With Pseudomonas
Posted on: Monday, 25 April 2005, 12:00 CDT
SEATTLE, April 25 /PRNewswire/ -- Corus Pharma has begun enrolling patients in its AIR-CF2 Phase 3 clinical trial for Aztreonam Lysinate for Inhalation (CAYSTON(TM) or AI). The multi-center, blinded, placebo controlled trial will be conducted in 50 cystic fibrosis (CF) centers in the United States, and will evaluate the efficacy and safety of AI in CF patients with pulmonary Pseudomonas aeruginosa. More detailed information on AI and the trial can be found at http://www.air-cf.com/ or http://www.clinicaltrials.gov/.
Aztreonam is an antibiotic that has activity against a broad spectrum of Gram-negative bacteria, including Pseudomonas aeruginosa, which commonly infect the lungs of CF patients. AI is a reconstituted solution which is specifically formulated for inhalation. Inhaled delivery concentrates the drug in the lungs, the predominant site of infection in CF patients. AI is delivered by the eFlow(R) Electronic Nebulizer developed by PARI GmbH with an average treatment time in Corus' Phase 2 clinical trial of less than three minutes.
"This is a significant milestone for the development of a potential treatment for cystic fibrosis patients and for our organization," comments A. Bruce Montgomery, M.D., CEO Corus Pharma. "We look forward to the results of this study so that we can submit Phase 3 clinical data to regulatory authorities."
About Cystic Fibrosis
Cystic Fibrosis is a genetic disease that affects approximately 30,000 children and adults in the United States and a similar number in Europe. A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, which traps bacteria and predisposes patients to infection, thereby continually damaging their lungs.
About Corus Pharma
Corus Pharma is committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and quality of life. More information about Corus Pharma may be found at http://www.coruspharma.com/. For more information about the AI Phase 3 clinical trials, go to http://www.air-cf.com/ or http://www.clinicaltrials.gov/.
Corus Pharma
CONTACT: Jonathan Mow of Corus Pharma, +1-206-792-3020, orjmow@coruspharma.com; or Leslie Cohan of Dave Syferd & Partners,+1-206-262-0395, or cell, +1-206-849-1810, or lcohan@dsandp.com, for CorusPharma
Web site: http://www.clinicaltrials.gov/
Web site: http://www.coruspharma.com/
Source: PRNewswire
Related Articles
- Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome
- RegeneRx/Sigma-Tau Complete Patient Enrollment of Second Phase II Clinical Trial With RGN-137
- RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial
- King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX
- Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis
- Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial With Its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus
- AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
- Kos Announces Completion of Patient Randomization for Jerini's Phase III Clinical Trials of Icatibant for the Subcutaneous Treatment of Hereditary Angioedema
- The Medicines Company Commences Patient Enrollment in Pivotal Phase III Clinical Trial of Cangrelor
- Amarin Reports Initiation of Enrollment and First Patient Dosing in Pivotal Phase III Clinical Trials for Miraxion in Huntington's Disease
 |
 |
User Comments (0)
RSS Feeds